A study exploring adjuvant capecitabine in early-stage TNBC failed but researchers are performing genomic analysis on a subset of patients who benefited.
Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.
Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.
The PAM50 breast cancer classifier successfully split prostate cancer samples into luminal and basal subtypes with ties to patient outcomes and treatment response.
A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.
In Science this week: gene mutation signatures linked to tobacco smoke, and more.
Researchers have developed a gene expression signature of healthy aging that can identify people at risk of Alzheimer's disease.
The study results also offer hints to new pathways that might be targeted to overcome resistance to currently used DNA methyltransferase inhibitors.
Led by former LabCorp executives, the firm is aiming to develop evidence around genetic signatures and license the tech to labs and Dx developers.
Skyline will collaborate with Janssen to develop a test to identify patients at increased risk of side effects from a multiple myeloma drug.
Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.
John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.